Spinal cord injury cervical – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Spinal cord injury cervical – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 An exploratory study to evaluate the effect of rimonabant on hand function in patients with cervical spinal cord injury https://clinicaltrials.eu/trial/an-exploratory-study-to-evaluate-the-effect-of-rimonabant-on-hand-function-in-patients-with-cervical-spinal-cord-injury/ Wed, 29 Apr 2026 15:10:06 +0000 https://clinicaltrials.eu/trial/an-exploratory-study-to-evaluate-the-effect-of-rimonabant-on-hand-function-in-patients-with-cervical-spinal-cord-injury/ This study focuses on individuals living with a spinal cord injury, which is damage to the bundle of nerves that sends signals between the brain and the rest of the body. The research specifically looks at people with injuries in the neck area, known as cervical spinal cord injury. The goal of this study is to evaluate the effect of rimonabant on improving how well the hands work.

Participants in this research will take rimonabant in the form of tablets. During the course of the study, various measurements will be taken to observe changes in hand strength, movement, and coordination. Other aspects of physical health, such as walking ability, balance, and fatigue, may also be monitored to understand how the medication affects the body overall.

]]> Study on the Safety of NG004 for Patients with Acute Spinal Cord Injury https://clinicaltrials.eu/trial/study-on-the-safety-of-ng004-for-patients-with-acute-spinal-cord-injury/ Wed, 29 Apr 2026 14:57:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-ng004-for-patients-with-acute-spinal-cord-injury/ This clinical trial is focused on studying a condition known as Acute Spinal Cord Injury, specifically when it affects the neck area, which is referred to as cervical spinal cord injury. The trial is investigating a new treatment using a human monoclonal antibody called NG004. Monoclonal antibodies are proteins made in a lab that can bind to substances in the body, including those that might be causing disease. In this study, NG004 is given as a solution for injection directly into the spinal canal, a method known as intrathecal use.

The purpose of the study is to evaluate the safety and tolerability of repeated injections of NG004 in patients who have recently experienced an acute spinal cord injury. Participants in the study will receive these injections over a period of several weeks. The study will monitor the type, frequency, and severity of any side effects or adverse reactions that may occur. Additionally, the study will assess various health indicators such as laboratory tests, heart function through an ECG (electrocardiogram), vital signs, physical and neurological examinations, muscle stiffness, and pain levels.

Throughout the study, researchers will also measure the levels of NG004 in the blood and in the cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord. This will help determine how the body processes the medication. The trial is expected to continue until September 2026, with recruitment of participants starting in December 2024. The findings from this study will contribute to understanding the potential of NG004 as a treatment for acute spinal cord injuries.

]]> Study on the Safety and Effectiveness of Elezanumab for Adults with Acute Traumatic Cervical Spinal Cord Injury https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-elezanumab-for-adults-with-acute-traumatic-cervical-spinal-cord-injury/ Wed, 29 Apr 2026 14:26:13 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-elezanumab-for-adults-with-acute-traumatic-cervical-spinal-cord-injury/ This clinical trial is focused on studying the effects of a treatment for Acute Traumatic Cervical Spinal Cord Injury. The treatment being tested is called Elezanumab, which is administered as a solution through an intravenous (IV) infusion. The study also includes a comparison with a Placebo Solution for Injection or Infusion.

The purpose of the study is to evaluate the safety and effectiveness of Elezanumab in individuals who have experienced a recent injury to the cervical region of their spinal cord. Participants in the study will receive either Elezanumab or a placebo and will be monitored for changes in their upper body motor function, which refers to the movement and strength of the arms and hands. The study will track these changes over a period of time to determine the impact of the treatment.

Throughout the study, participants will undergo regular assessments to measure their progress. These assessments will include evaluations of their ability to perform daily activities independently and any improvements in their motor skills. The study aims to provide valuable insights into the potential benefits of Elezanumab for individuals with this type of spinal cord injury.

]]>